Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Gepotidacin is a new antibiotic that may potentially be used to treat prostatic infections
and pharyngeal gonorrhoea. To date, no data exists on gepotidacin pharmacokinetics in those
tissues. The present study is being carried out to determine concentrations of gepotidacin in
plasma, prostate and tonsillar tissue of patients undergoing radical prostatectomy (RPE) for
localized prostate, simple prostatectomy (PE) for benign prostate hyperplasia (BPH) or
tonsillectomy (TE). This will contribute to a more complete understanding of the drug's
penetration to its site of action.
Phase:
Phase 1
Details
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France